The Effect of the MTHFR C677T Genotype Polymorphism on the Efficacy of Folic Acid Treatment for Hyperhomocysteinemia and Cardiovascular Endothelial Function
Chronic Diseases and Translational Medicine · 2026
DOI: 10.1002/cdt3.70068 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chronic Diseases and Translational Medicine, 2026. Verfasst von Xiaohui Dou und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Management Zhuhai People's Hospital Zhuhai Guangdong China. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Cardiovascular disease remains a major public health burden. This study aimed to investigate the effect of the methylenetetrahydrofolate reductase (MTHFR) C677T genotype on folic acid treatment response and cardiovascular endothelial function in patients with hyperhomocysteinemia (HHcy).
Methods
We retrospectively enrolled 344 patients with HHcy genotyped for MTHFR C677T (CC, n = 141; CT, n = 169; and TT, n = 34). Plasma homocysteine (Hcy) concentrations and vascular function indicators were measured at baseline and 2, 4, and 12 months. Repeated‐measures one‐way analysis of variance, Kaplan–Meier analysis, and multivariate logistic regression were applied.
Results
After treatment, the Hcy concentration and pulse wave velocity decreased over time in all genotype groups, whereas the ankle‐brachial index increased. Significant main effects of time were observed for Hcy concentration ( F = 173.52, p < 0.01), pulse wave velocity ( F = 52.84, p < 0.01), and ankle‐brachial index ( F = 94.17, p < 0.01). At each time point, patients with CC showed better values than patients with CT and TT for all parameters ( p < 0.05) except for intima‐media thickness in patients with TT, which showed no significant changes ( p > 0.05). Patients with CC also had the highest Hcy concentration target achievement rate (81.6%, p < 0.01 vs. CT and TT). Patients with the CC genotype had the highest cumulative Hcy concentration target achievement rate (81.6%), which was higher than that of patients with the CT and TT genotypes ( p < 0.01). Multivariate logistic regression showed that the CT (OR = 0.320, 95% CI: 0.179–0.572) and TT (OR = 0.080, 95% CI: 0.019–0.326) genotypes were independent negative predictors of target achievement, whereas higher folate metabolism capacity was a positive predictor.
Conclusion
MTHFR C677T polymorphism significantly affects folic acid efficacy and endothelial improvement. Patients with the TT genotype had lower therapeutic efficacy of folic acid therapy. Genotyping may help estimate treatment responses and support individualized follow‐up.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Health Management Zhuhai People's Hospital Zhuhai Guangdong China.
ORCID-Profile: Xiaohui Dou
Zitieren
APA
Dou, X., Zhang, X., Zeng, L., Zeng, L., Hu, X., Jiang, X., Wan, Y., Ge, M., & Huang, X. (2026). The Effect of the MTHFR C677T Genotype Polymorphism on the Efficacy of Folic Acid Treatment for Hyperhomocysteinemia and Cardiovascular Endothelial Function. Chronic Diseases and Translational Medicine. https://doi.org/10.1002/cdt3.70068
Vancouver
Dou X, Zhang X, Zeng L, Zeng L, Hu X, Jiang X, et al. The Effect of the MTHFR C677T Genotype Polymorphism on the Efficacy of Folic Acid Treatment for Hyperhomocysteinemia and Cardiovascular Endothelial Function. Chronic Diseases and Translational Medicine. 2026. doi:10.1002/cdt3.70068
BibTeX
@article{Dou2026,
author = {Dou, Xiaohui and Zhang, Xijuan and Zeng, Liang and Zeng, Liheng and Hu, Xiaoyan and Jiang, Xuhong and Wan, Yahui and Ge, Mingxia and Huang, Xiaoyan},
title = {The Effect of the MTHFR C677T Genotype Polymorphism on the Efficacy of Folic Acid Treatment for Hyperhomocysteinemia and Cardiovascular Endothelial Function},
journal = {Chronic Diseases and Translational Medicine},
year = {2026},
doi = {10.1002/cdt3.70068}
}
EUVIMED